Sie befinden sich hier:

Projekt LipidCardio

Langtitel: Lipoprotein a – genetische Assoziationen und Arteriosklerose bei kardiovaskulären Risikofaktoren
Akronym: LipidCardio
Projektförderung: Sanofi-Aventis Deutschland GmbH
Förderzeitraum: 01.04.2016 bis 31.12.2018
Projektleitung: Prof. Dr. Elisabeth Steinhagen-Thiessen und PD Dr. Ilja Demuth
Kooperationspartner: Prof. Dr. Ulf Landmesser und PD Dr. David Leistner
Studienarzt: Dr. Maximilian König
Patientenkollektiv: N≈1.000 Patienten aus der Medizinischen Klinik für Kardiologie, CBF
Datenerhebungsphase: 25.10.2016 bis 28.02.2018

Study synopsis
The LipidCardio Study is a collaboration project between the Lipid Clinic at the Interdisciplinary Metabolism Center, Campus Virchow and the Department of Cardiology, Campus Benjamin Franklin (both Charité - Universitätsmedizin Berlin).
The LipidCardio study is a prospective observational study with a focus on the prevalence and correlates of lipoprotein(a) [Lp(a)] among patients undergoing cardiac catheterization for angiographic evaluation of coronary artery disease (CAD). The aim of the study is a better understanding of the role of Lp(a) in the context of cardiovascular diseases, as well as in the development of diabetes mellitus type II.
As a first step, the focus lies on extensive phenotyping and exploration of cross-sectional associations. Routine laboratory data are collected, and a comprehensive lipid profile including Lp(a) is drawn. Furthermore, comprehensive clinical data are collected, comprising diagnoses, medication, family history, anthropometric measurements, echocardiography, coronary angiography, blood pressure and pulse wave velocity measurement, lifestyle factors (alcohol, smoking, physical activity), the Seattle Angina Questionnaire, Folstein’s Mini-Mental State Examination and nutrition. In addition, DNA is collected from all participants for molecular genetic analyses. Additional blood samples are stored in a central biobank (ZeBanC), providing an opportunity for additional measurements later.
In a subsequent step, participants with elevated Lp(a) are to represent a cohort, with the possibility of longitudinal follow-ups.